Life sciences team advises AstraZeneca on key transaction for vaccine for respiratory illnesses

01 September 2017
Client work

MEDI8897 is a monoclonal antibody that helps prevent lower respiratory tract illnesses caused by a virus that is the biggest cause of LRTI among infants and young children.

The agreement sees Sanofi Pasteur make an upfront payment of €120 million, plus a further payment of up to €495 million upon achievement of certain development and sales-related milestones. The companies will share all costs and profits equally and AstraZeneca will continue to lead all development activity.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences

Related Insights & Resources

View all insights Related Insights & Resources
Video that provides an update on pharma regulatory issues in Russia in 2021 Articles
26 February 2021 Russia, February 2021: Update on Pharma Regulatory Issues
scientist in lab looking at microscope On-demand webinar
24 February 2021 Global perspectives - Preliminary injunctions in life sciences CLE/CPD:1 hour
Calendar and hourglass with time slipping away Articles
17 February 2021 Patented medicines regulations -
No implied limitation period in
section 8.2
Download or print PDF